Argent BioPharma Limited (ASX:RGT)

Australia flag Australia · Delayed Price · Currency is AUD
0.0800
0.00 (0.00%)
At close: Aug 1, 2025, 4:00 PM AEST
Market Cap5.77M
Revenue (ttm)295.83K
Net Income (ttm)-22.62M
Shares Out72.18M
EPS (ttm)-0.45
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume25,000
Average Volume32,975
Open0.0750
Previous Close0.0800
Day's Range0.0750 - 0.0800
52-Week Range0.0700 - 0.5700
Beta0.48
RSI46.56
Earnings DateAug 29, 2025

About Altus Power

Argent BioPharma Limited, a multidisciplinary drug development Company, engages in the provision of medicines targeting immunology and neurology worldwide. The company’s principal product candidates include CimetrA, which is in phase IIB clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer. It is also involved in the preclinical development of Irnican for the tr... [Read more]

Sector Healthcare
Founded 2014
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol RGT
Full Company Profile

Financial Performance

In 2024, Argent BioPharma's revenue was 891,083, a decrease of -73.70% compared to the previous year's 3.39 million. Losses were -17.53 million, -15.81% less than in 2023.

Financial Statements

News

There is no news available yet.